Concepts (215)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Squamous Cell | 16 | 2023 | 1098 | 1.590 |
Why?
|
| Mouth Neoplasms | 10 | 2023 | 199 | 1.390 |
Why?
|
| Head and Neck Neoplasms | 11 | 2023 | 1061 | 0.960 |
Why?
|
| Neovascularization, Pathologic | 6 | 2010 | 354 | 0.770 |
Why?
|
| Receptor, EphB4 | 2 | 2013 | 23 | 0.520 |
Why?
|
| Biomarkers, Tumor | 5 | 2020 | 1545 | 0.440 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2009 | 293 | 0.440 |
Why?
|
| Proto-Oncogene Proteins c-met | 5 | 2017 | 199 | 0.420 |
Why?
|
| Esophageal Neoplasms | 2 | 2012 | 332 | 0.420 |
Why?
|
| DNA, Neoplasm | 2 | 2020 | 266 | 0.310 |
Why?
|
| Angiogenic Proteins | 1 | 2008 | 17 | 0.300 |
Why?
|
| Oligopeptides | 1 | 2009 | 188 | 0.300 |
Why?
|
| Disease Models, Animal | 4 | 2013 | 2393 | 0.290 |
Why?
|
| Lung Neoplasms | 6 | 2014 | 2370 | 0.270 |
Why?
|
| Cell Nucleolus | 1 | 2006 | 25 | 0.260 |
Why?
|
| Precancerous Conditions | 2 | 2009 | 201 | 0.260 |
Why?
|
| Cell Line, Tumor | 9 | 2014 | 2587 | 0.260 |
Why?
|
| Hepatocyte Growth Factor | 3 | 2011 | 84 | 0.260 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2006 | 153 | 0.250 |
Why?
|
| Cell Movement | 7 | 2016 | 786 | 0.230 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 2 | 2017 | 36 | 0.230 |
Why?
|
| Immunohistochemistry | 5 | 2017 | 1801 | 0.220 |
Why?
|
| Plasminogen Activator Inhibitor 2 | 1 | 2003 | 2 | 0.220 |
Why?
|
| Vascular Endothelial Growth Factor A | 5 | 2009 | 405 | 0.210 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2006 | 296 | 0.210 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2024 | 132 | 0.200 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2016 | 485 | 0.200 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2013 | 160 | 0.190 |
Why?
|
| Neoadjuvant Therapy | 1 | 2024 | 376 | 0.180 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2017 | 1284 | 0.180 |
Why?
|
| Saliva | 1 | 2020 | 124 | 0.170 |
Why?
|
| Transforming Growth Factor alpha | 1 | 1999 | 50 | 0.170 |
Why?
|
| Dental Alloys | 1 | 2018 | 5 | 0.150 |
Why?
|
| Orthodontic Appliances | 1 | 2018 | 7 | 0.150 |
Why?
|
| Transforming Growth Factor beta | 2 | 2001 | 326 | 0.150 |
Why?
|
| Gene Dosage | 3 | 2013 | 210 | 0.150 |
Why?
|
| Mice | 8 | 2016 | 11851 | 0.150 |
Why?
|
| Antineoplastic Agents | 3 | 2014 | 2331 | 0.140 |
Why?
|
| Life Style | 1 | 2018 | 176 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2024 | 2506 | 0.140 |
Why?
|
| Tissue Array Analysis | 2 | 2017 | 126 | 0.140 |
Why?
|
| Gene Expression | 3 | 2013 | 1309 | 0.140 |
Why?
|
| Humans | 27 | 2024 | 89970 | 0.130 |
Why?
|
| Immunoblotting | 2 | 2017 | 272 | 0.130 |
Why?
|
| Tumor Cells, Cultured | 5 | 2016 | 1048 | 0.130 |
Why?
|
| Calgranulin A | 1 | 2016 | 11 | 0.130 |
Why?
|
| Gene Expression Profiling | 4 | 2010 | 1452 | 0.130 |
Why?
|
| Calgranulin B | 1 | 2016 | 15 | 0.130 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2014 | 1131 | 0.120 |
Why?
|
| Adenocarcinoma | 2 | 2012 | 1185 | 0.120 |
Why?
|
| Receptors, Opioid, mu | 1 | 2014 | 45 | 0.120 |
Why?
|
| Animals | 10 | 2022 | 27528 | 0.110 |
Why?
|
| Niacinamide | 1 | 2013 | 98 | 0.110 |
Why?
|
| Indazoles | 1 | 2013 | 60 | 0.110 |
Why?
|
| Receptors, Growth Factor | 2 | 2011 | 52 | 0.110 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2014 | 189 | 0.110 |
Why?
|
| Paxillin | 1 | 2013 | 58 | 0.110 |
Why?
|
| 4-Nitroquinoline-1-oxide | 2 | 2010 | 15 | 0.110 |
Why?
|
| Mice, Inbred CBA | 2 | 2010 | 53 | 0.100 |
Why?
|
| ErbB Receptors | 3 | 2010 | 499 | 0.100 |
Why?
|
| Focal Adhesions | 1 | 2013 | 70 | 0.100 |
Why?
|
| Mitochondrial Dynamics | 1 | 2013 | 56 | 0.100 |
Why?
|
| Carcinogens | 2 | 2010 | 111 | 0.100 |
Why?
|
| Interleukin-8 | 3 | 2008 | 86 | 0.100 |
Why?
|
| Barrett Esophagus | 1 | 2012 | 94 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2013 | 586 | 0.100 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 283 | 0.100 |
Why?
|
| Mesothelioma | 1 | 2014 | 323 | 0.090 |
Why?
|
| Tissue Banks | 1 | 2011 | 16 | 0.090 |
Why?
|
| Thoracic Neoplasms | 1 | 2011 | 66 | 0.090 |
Why?
|
| Carcinoma | 1 | 2013 | 438 | 0.080 |
Why?
|
| Piperidines | 1 | 2010 | 163 | 0.080 |
Why?
|
| Quinazolines | 1 | 2010 | 212 | 0.080 |
Why?
|
| Ki-67 Antigen | 1 | 2009 | 67 | 0.080 |
Why?
|
| Microvessels | 1 | 2009 | 69 | 0.080 |
Why?
|
| Loss of Heterozygosity | 3 | 2017 | 86 | 0.080 |
Why?
|
| Macrophages | 2 | 2002 | 582 | 0.080 |
Why?
|
| Mutation, Missense | 1 | 2010 | 281 | 0.080 |
Why?
|
| Cell Proliferation | 4 | 2016 | 1669 | 0.080 |
Why?
|
| Stomach Neoplasms | 1 | 2011 | 288 | 0.080 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2008 | 57 | 0.070 |
Why?
|
| Paclitaxel | 2 | 2024 | 474 | 0.070 |
Why?
|
| Databases, Factual | 1 | 2011 | 866 | 0.070 |
Why?
|
| Medical Oncology | 1 | 2011 | 384 | 0.070 |
Why?
|
| Disease Progression | 3 | 2014 | 1469 | 0.070 |
Why?
|
| Computational Biology | 1 | 2010 | 551 | 0.070 |
Why?
|
| Thrombospondin 1 | 1 | 2006 | 21 | 0.070 |
Why?
|
| Antibodies | 1 | 2008 | 353 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2006 | 125 | 0.060 |
Why?
|
| MicroRNAs | 1 | 2010 | 556 | 0.060 |
Why?
|
| Keratinocytes | 2 | 2003 | 146 | 0.060 |
Why?
|
| Prognosis | 4 | 2018 | 3798 | 0.060 |
Why?
|
| Drug Synergism | 2 | 2014 | 307 | 0.050 |
Why?
|
| Mice, Nude | 2 | 2016 | 816 | 0.050 |
Why?
|
| Carboplatin | 1 | 2024 | 312 | 0.050 |
Why?
|
| Male | 5 | 2024 | 42682 | 0.050 |
Why?
|
| Culture Media, Conditioned | 2 | 2001 | 103 | 0.050 |
Why?
|
| Chromosome Mapping | 1 | 2006 | 1074 | 0.050 |
Why?
|
| STAT3 Transcription Factor | 2 | 2013 | 86 | 0.050 |
Why?
|
| Neoplasm Staging | 3 | 2016 | 2000 | 0.050 |
Why?
|
| Tumor Burden | 2 | 2013 | 310 | 0.050 |
Why?
|
| Female | 7 | 2024 | 46595 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2022 | 293 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2023 | 251 | 0.050 |
Why?
|
| Genetic Markers | 1 | 2003 | 476 | 0.050 |
Why?
|
| Tretinoin | 1 | 2002 | 128 | 0.050 |
Why?
|
| Chemoprevention | 1 | 2001 | 92 | 0.050 |
Why?
|
| Models, Animal | 1 | 2022 | 277 | 0.050 |
Why?
|
| Papillomavirus Infections | 1 | 2024 | 264 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 885 | 0.050 |
Why?
|
| Neovascularization, Physiologic | 1 | 2001 | 143 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2003 | 693 | 0.040 |
Why?
|
| RNA, Small Interfering | 2 | 2013 | 557 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2003 | 449 | 0.040 |
Why?
|
| Cisplatin | 1 | 2022 | 598 | 0.040 |
Why?
|
| Mutation | 3 | 2020 | 4168 | 0.040 |
Why?
|
| Gingival Neoplasms | 1 | 1999 | 1 | 0.040 |
Why?
|
| Gallbladder Neoplasms | 1 | 1999 | 23 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 476 | 0.040 |
Why?
|
| Bacteria | 1 | 2023 | 486 | 0.040 |
Why?
|
| Apoptosis | 2 | 2016 | 1718 | 0.040 |
Why?
|
| Oral Health | 1 | 2018 | 10 | 0.040 |
Why?
|
| Cell Division | 1 | 1999 | 692 | 0.040 |
Why?
|
| Aged | 3 | 2024 | 19254 | 0.040 |
Why?
|
| Tongue Neoplasms | 1 | 2018 | 52 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2018 | 221 | 0.040 |
Why?
|
| Liquid Biopsy | 1 | 2017 | 36 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 1999 | 569 | 0.040 |
Why?
|
| Metals | 1 | 2018 | 93 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2003 | 2767 | 0.030 |
Why?
|
| Fibroblasts | 1 | 1999 | 759 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 1352 | 0.030 |
Why?
|
| Middle Aged | 3 | 2024 | 26148 | 0.030 |
Why?
|
| Skin | 1 | 1999 | 589 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2017 | 529 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2018 | 274 | 0.030 |
Why?
|
| Pyrrolidinones | 1 | 2014 | 14 | 0.030 |
Why?
|
| Sex Factors | 1 | 2018 | 1075 | 0.030 |
Why?
|
| Quinolines | 1 | 2014 | 86 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 1999 | 2887 | 0.030 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2014 | 91 | 0.030 |
Why?
|
| Quality of Life | 1 | 2022 | 1682 | 0.030 |
Why?
|
| Imidazoles | 1 | 2014 | 140 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2014 | 137 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2014 | 268 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2016 | 1091 | 0.030 |
Why?
|
| Incidence | 1 | 2018 | 1603 | 0.030 |
Why?
|
| Autopsy | 1 | 2013 | 122 | 0.030 |
Why?
|
| Age Factors | 1 | 2018 | 1880 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2014 | 508 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 495 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2013 | 696 | 0.030 |
Why?
|
| Models, Biological | 1 | 1999 | 1766 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factors | 2 | 2002 | 56 | 0.020 |
Why?
|
| Wound Healing | 1 | 2014 | 361 | 0.020 |
Why?
|
| Endothelial Growth Factors | 2 | 2002 | 55 | 0.020 |
Why?
|
| Lymphokines | 2 | 2002 | 75 | 0.020 |
Why?
|
| Adult | 2 | 2024 | 26822 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2014 | 1130 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2014 | 371 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2013 | 3404 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2013 | 310 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2013 | 646 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2018 | 2887 | 0.020 |
Why?
|
| Cell Survival | 1 | 2013 | 983 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2014 | 538 | 0.020 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2010 | 67 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2011 | 352 | 0.020 |
Why?
|
| Quinolones | 1 | 2010 | 56 | 0.020 |
Why?
|
| Biopsy | 1 | 2014 | 1184 | 0.020 |
Why?
|
| Peptides | 1 | 2013 | 649 | 0.020 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2010 | 98 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2010 | 80 | 0.020 |
Why?
|
| Paraffin Embedding | 1 | 2010 | 78 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2013 | 2064 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2010 | 106 | 0.020 |
Why?
|
| Protein Interaction Mapping | 1 | 2010 | 81 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2013 | 1498 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 2655 | 0.020 |
Why?
|
| Indoles | 1 | 2011 | 300 | 0.020 |
Why?
|
| Receptor, ErbB-2 | 1 | 2011 | 247 | 0.020 |
Why?
|
| Piperazines | 1 | 2011 | 283 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2010 | 283 | 0.020 |
Why?
|
| DNA Primers | 1 | 2010 | 543 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2011 | 319 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2010 | 426 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 793 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2010 | 690 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2011 | 665 | 0.020 |
Why?
|
| Risk Factors | 1 | 2018 | 5559 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2010 | 605 | 0.020 |
Why?
|
| Base Sequence | 1 | 2010 | 2329 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2010 | 1066 | 0.020 |
Why?
|
| Young Adult | 1 | 2018 | 6410 | 0.020 |
Why?
|
| Genome, Human | 1 | 2010 | 791 | 0.020 |
Why?
|
| United States | 1 | 2018 | 7108 | 0.020 |
Why?
|
| Adolescent | 1 | 2018 | 9342 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2018 | 9210 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2014 | 6783 | 0.010 |
Why?
|
| Matched-Pair Analysis | 1 | 2003 | 40 | 0.010 |
Why?
|
| Human Genome Project | 1 | 2003 | 19 | 0.010 |
Why?
|
| Macrophage Activation | 1 | 2002 | 49 | 0.010 |
Why?
|
| Chemokine CCL2 | 1 | 2001 | 47 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2001 | 72 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 2001 | 154 | 0.010 |
Why?
|
| Cornea | 1 | 2001 | 70 | 0.010 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2001 | 89 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2001 | 176 | 0.010 |
Why?
|
| Monocytes | 1 | 2002 | 221 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2010 | 2363 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2001 | 700 | 0.010 |
Why?
|
| Cell Line | 1 | 2001 | 2495 | 0.010 |
Why?
|
| Phenotype | 1 | 2002 | 2458 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2001 | 1396 | 0.010 |
Why?
|
| Rats | 1 | 2001 | 4048 | 0.010 |
Why?
|